In the latest from Washington concerning healthcare, a couple of key updates for this month should be noted. The Drug Enforcement Administration (DEA) has deemed it prudent to extend COVID-19 era flexibilities for telehealth for the second time. In tandem, the House is under consideration for new leadership roles.
Drawing on the current health crisis, the DEA has seen the value in extending leniancy for telehealth. This speaks to the changing landscape in healthcare services prompted by the pandemic. As face-to-face appointments became high risk through COVID-19, institutions and officials have had to adapt.
In addition to the DEA’s decision, the House is in the middle of reconsidering its leadership roles. While the specifics of these considerations are yet to be defined, their outcome could potentially have a significant influence on healthcare laws and regulations.
As the landscape of healthcare fluctuates in response to current health crises, changes in regulations and governance are inevitable.
To view the full article, follow the link here.